Sanofi boosts case for Toujeo with real-world data presentation

20 March 2018

Real-world data presented by France’s Sanofi (Euronext: SAN) show that the firm’s once-daily long-acting basal analogue Toujeo (gla-300) is associated with statistically significant improvements in HbA1c in patients with type 1 diabetes.

Toujeo, a more concentrated version of the company’s insulin workhorse Lantus (insulin glargine), was approved by the US Food and Drug Administration in early 2015.

The primary objective of the study was to describe the change in HbA1c levels from baseline to six months following initiation of gla-300 in patients with type 1 diabetes. The data show a statistically significant reduction in this regard.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK